IRIC discoveries have spurred major advances in understanding the development of cancer and opened the way to the creation of new, more targeted therapeutic solutions. Its publications are a reflection of these accomplishments. They also demonstrate the Institute’s drive and productivity.
Heart failure drug proscillaridin A targets MYC overexpressing leukemia through global loss of lysine acetylation.J. Exp. Clin. Cancer Res. 2019-06-13;38(1):251.
Apelin protects against abdominal aortic aneurysm and the therapeutic role of neutral endopeptidase resistant apelin analogs.Proc. Natl. Acad. Sci. U.S.A. 2019-06-12.
Pediatric leukemia: Moving toward more accurate models.Exp. Hematol. 2019-05-30.
Petite Integration Factor 1 (PIF1) helicase deficiency increases weight gain in Western diet-fed female mice without increased inflammatory markers or decreased glucose clearance.PLoS ONE 2019-05-28;14(5):e0203101.
Allodepleted T-cell immunotherapy after haploidentical haematopoietic stem cell transplantation without severe acute graft-versus-host disease (GVHD) in the absence of GVHD prophylaxis.Br. J. Haematol. 2019-05-28.
Hybridization of β-Adrenergic Agonists and Antagonists Confers G Protein Bias.J. Med. Chem. 2019-05-23;62(10):5111-5131.
PTEN reduces endosomal PtdIns(4,5)P2 in a phosphatase-independent manner via a PLC pathway.J. Cell Biol. 2019-05-22.
Predisposing germline mutations in high hyperdiploid acute lymphoblastic leukemia in children.Genes Chromosomes Cancer 2019-05-18.